$GALT
GALECTIN THERAPEUTICS INC
Runway:11 mo
NasdaqMarket cap: —CIK 0001133416
Upcoming catalysts
0 surfacedNo catalysts surfaced for GALT yet.
Drug pipeline
Recent & active trials
| NCT | Drug | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04365868 | belapectin | Phase 3 | Terminated | 2025-03-11 |
| NCT04332432 | belapectin | Phase 1 | Completed | 2022-03-09 |
| NCT02407041 | GR-MD-02 | Phase 2 | Completed | 2018-03-01 |
| NCT02462967 | GR-MD-02 | Phase 2 | Completed | 2017-10-01 |
| NCT02421094 | GR-MD-02 | Phase 2 | Completed | 2016-09-27 |
| NCT01899859 | GR-MD-02 | Phase 1 | Completed | 2015-02-01 |
| NCT00388700 | GM-CT-01 | Phase 2 | Withdrawn | 2009-06-01 |
| NCT00386516 | GM-CT-01 | Phase 2 | Withdrawn | 2009-06-01 |
| NCT00110721 | GM-CT-01 plus 5-Fluorouracil | Phase 2 | Terminated | 2007-06-01 |
| NCT00054977 | GM-CT-01 | Phase 1 | Completed | 2005-04-01 |